Intuitive Surgical (ISRG) Stock Forecast & Price Target

Intuitive Surgical is viewed favorably because it leads a still underpenetrated robotic surgery market with a durable ecosystem spanning da Vinci systems, instruments, training, service, and clinical evidence, supported by more than 11,000 systems placed worldwide and over 16MM procedures performed. Its fundamentals remain strong, with Q2'26 revenue of $2.89B, EPS of $2.80, gross margin of 70.0%, and operating margin near 42%, while 468 system placements and 12% installed-base growth underscore continued demand. Long-term adoption should be reinforced by mid-teens procedure growth, a stable U.S. capital environment with about 70% of systems leased, and new initiatives like DV5, XiR, and the 1H'27 extended-use program that can expand access and deepen the moat.

Intuitive Surgical is facing a weakening fundamental setup as its premium valuation has deteriorated amid increased competition, economic and capital pressure, and limited procedure growth. U.S. da Vinci procedure growth slowed to 12% y/y in Q2'26 from 14% in Q1'26, while management cited deferrals in elective categories, GLP-1 headwinds in bariatrics, and the law of large numbers as the installed base scales. Despite more than 11,000 systems worldwide and guidance for 13.5%-15.5% procedural growth, the outlook remains pressured by hospital capital budget constraints, slower system sales from a lengthening trade-in cycle, and rising operating expenses that can cap earnings leverage.